10 research outputs found

    Modelling of networked measuring systems -- from white-box models to data based approaches

    Get PDF
    Mathematical modelling is at the core of metrology as it transforms raw measured data into useful measurement results. A model captures the relationship between the measurand and all relevant quantities on which the measurand depends, and is used to design measuring systems, analyse measured data, make inferences and predictions, and is the basis for evaluating measurement uncertainties. Traditional modelling approaches are typically analytical, for example, based on principles of physics. But with the increasing use of digital technologies, large sensor networks and powerful computing hardware, these traditional approaches are being replaced more and more by data-driven methods. This paradigm shift holds true in particular for the digital future of measurement in all spheres of our lives and the environment, where data provided by large and complex interconnected systems of sensors are to be analysed. Additionally, there is a requirement for existing guidelines and standards in metrology to take the paradigm shift into account. In this paper we lay the foundation for the development from traditional to data-driven modelling approaches. We identify key aspects from traditional modelling approaches and discuss their transformation to data-driven modelling

    Ultimate Taipan with Dynamic Block Encoding : (Competition Contribution)

    No full text
    Ultimate Taipan is a software model checker that uses trace abstraction and abstract interpretation to prove correctness of programs. In contrast to previous versions, Ultimate Taipan now uses dynamic block encoding to obtain the best precision possible when evaluating transition formulas of large block encoded programs.publishe

    Ultimate Automizer and the Search for Perfect Interpolants : (Competition Contribution)

    No full text
    Ultimate Automizer is a software verifier that generalizes proofs for traces to proofs for larger parts for the program. In recent years the portfolio of proof producers that are available to Ultimate has grown continuously. This is not only because more trace analysis algorithms have been implemented in Ultimate but also due to the continuous progress in the SMT community. In this paper we explain how Ultimate Automizer dynamically selects trace analysis algorithms and how the tool decides when proofs for traces are “good” enough for using them in the abstraction refinement.publishe

    Mast Cell Leukemia: Clinical and Molecular Features and Survival Outcomes of Patients in the ECNM Registry

    Get PDF
    Mast cell leukemia (MCL) is a rare subtype of systemic mastocytosis (SM) defined by >20% mast cells (MC) on a bone marrow aspirate. We evaluated 92 patients with MCL from the European Competence Network on Mastocytosis registry. Thirty-one (34%) patients had a diagnosis of MCL with an associated hematologic neoplasm (MCL-AHN). Chronic MCL (lack of C-findings) comprised 14% of patients, and only 4.5% had 'leukemic MCL' (≥ 10% circulating MCs). KIT D816V was found in 62/85 (73%) evaluable patients; 9 (11%) individuals exhibited alternative KIT mutations, and no KIT variants were detected in 14 (17%) subjects. Ten evaluable patients (17%) had an abnormal karyotype and the poor-risk SRSF2, ASXL1, and RUNX1 (S/A/R) mutations were identified in 16/36 (44%) patients who underwent next-generation sequencing. Midostaurin was the most common therapy, administered to 65% of patients, and 45% as first-line therapy. The median overall survival (OS) was 1.6 years. In multivariate analysis (S/A/R mutations excluded due to low event rates), a diagnosis of MCL-AHN (HR 4.7, 95% CI 1.7 - 13.0, p = 0.001) and abnormal karyotype (HR 5.6, 95% CI 1.4 - 13.3, p = 0.02) were associated with inferior OS; KIT D816V positivity (HR 0.33, 95% CI 0.11 - 0.98, p = 0.04) and midostaurin treatment (HR 0.32, 95% CI 0.08 - 0.72, p = 0.008) were associated with superior OS. These data provide the most comprehensive snapshot of the clinicopathologic, molecular, and treatment landscape of MCL to date, and should help further inform subtyping and prognostication of MCL
    corecore